Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studySylvie Castaigné, Hervé Dombret, Cécile Pautas et al.|The Lancet|2012Cited by 994
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA)Claude Preudhomme, Hervé Dombret, Jean‐Michel Cayuela et al.|Blood|2002Cited by 503
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaÉric Jourdan, Hervé Dombret, Nicolas Boissel et al.|Blood|2013Cited by 357
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)Nicolas Boissel, Claude Preudhomme, Harmony Leroy et al.|Leukemia|2006Cited by 355
Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trialJuliette Lambert, Sylvie Castaigné, Cécile Pautas et al.|Haematologica|2018Cited by 349